Company / Operating Income
Collegium Pharmaceutical, Inc. Operating Income History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income
$179.6M
FY2025
5-year range
$17.6M / $179.6M
FY2021-FY2025
Trend
+5.7%
vs FY2024
Sector context
#28 of 204
Health Care
What the data says
Collegium Pharmaceutical, Inc.'s operating income of $180M is higher than 86% of companies in the Health Care sector (FY2025). Operating Income has increased for 4 consecutive years, from $18M in FY2021 to $180M in FY2025.
Based on SEC 10-K filings.
$180M in FY2025 with a 5-year CAGR of +26.1%. Top quartile in the Health Care sector.
Improved from $167M to $180M over the past 2 years.
Health Care sector context is included.
Operating Income over time
Growth rates
- 3-Year CAGR
- +75.3%
- 5-Year CAGR
- +26.1%
- 10-Year CAGR
- -
Sector benchmark
+66.8% above sector average
Key checks
Key Insights
- Collegium Pharmaceutical, Inc.'s operating income has grown for 4 consecutive years.
- 5-year CAGR of +26.1%, indicating consistent growth.
- In FY2025, operating income increased 5.7% year-over-year.
- Ranks #28 out of 204 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 0.96 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $179.6M | +5.7% |
| FY2024 | $169.9M | +1.8% |
| FY2023 | $167.0M | +401.1% |
| FY2022 | $33.3M | +89.0% |
| FY2021 | $17.6M | -68.7% |
| FY2020 | $56.2M | +336.8% |
| FY2019 | -$23.7M | -14.8% |
| FY2018 | -$20.7M | +23.1% |
| FY2017 | -$26.9M | +71.4% |
| FY2016 | -$94.1M | -249.7% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026